How much do PBMs save patients and pharmacy benefit plans?

How much do PBMs save patients and pharmacy benefit plans?

There are a lot of great benefits to having a pharmacy benefit management company — or PBM for short — including access to needed drugs, monitoring of drug efficacy and prevention of possibly dangerous drug interactions. But the benefit that really hits home is the money that PBMs can save pharmacy patients and their benefit plans.

How much do PBMs save? Here are the details.

According to the Pharmaceutical Care Management Association (PCMA), PBMs save patients and health plans $123 per brand prescriptions. These savings are generated through rebate programs, direct negotiation with pharmaceutical manufacturers and programs to manage and control the total cost of prescription medicine to the consumer as noted by the U.S. Government Accountability Office (GAO).

Additionally, according to the Federal trade Commission, PBMs achieve cost-savings by encouraging competition for more generic medicines, helping reduce prescription drug costs for more than 266 million Americans.

This all results in an average yearly savings of nearly $1,000 per person.

PBMs save money and save lives

Savings and safety go hand-in-hand when a PBM is involved in the procurement and delivery of prescription medicines for patients. It’s estimated that every single year, PBMs will help prevent more than 100 million medication errors by reviewing newly prescribed drugs, checking for drug interactions and alerting pharmacies and doctors of potential risks. 

This careful oversight results in healthier patients and fewer mishaps. One study shows that, for diabetes patients, PBMs help prevent more than 480,000 heart failures, 230,000 cases of kidney disease, 180,000 strokes and 8,000 amputations. Every single year.For more about how VativoRx can help as your PBM, reach out to us on our contact page, or call 888-488-5750 to speak directly with a PBM specialist.

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »